GLP1R and type 2 diabetes mellitus: Thus, we show that both SGLT2 inhibitors and GLP-1 receptor agonists offer cardiovascular protection in T2DM, withSGLT2i providing a modest advantage in reducing MACE and a significant benefit in lowering heart failure hospitalizations.